Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Who May Qualify: - A diagnosis of progressive MS (secondary; SPMS or primary; PPMS) according to the 2013 revisions of clinical course of multiple sclerosis and the 2017 revisions of the McDonald criteria. - Aged 18-65 years. - EDSS 3-6.5 - Able to perform T25FW test - The participant must have documented evidence of disability progression observed during the 24 months before screening. - With or without a stable disease modifying therapy during the last three months. - Written willing to sign a consent form for study participation. Who Should NOT Join This Trial: - A diagnosis of relapsing MS according to the revisions of the McDonald criteria - Neoplastic disease at baseline - Previous history of malignant melanoma or breast cancer - Stable phase of a progressive disease course - Pregnancy or lactating female patients - Dementia or other neurodegenerative disorder at baseline visit - Comorbidity (psychiatric or somatic) that precludes study participation - Use of high dose vitamin B3 supplementation within 30 days of enrolment - Genetically confirmed mitochondrial disease or metabolic disorder Always talk to your doctor about whether this trial is right for you.